1. Home
  2. ALVR vs EYEN Comparison

ALVR vs EYEN Comparison

Compare ALVR & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALVR
  • EYEN
  • Stock Information
  • Founded
  • ALVR 2013
  • EYEN 2014
  • Country
  • ALVR United States
  • EYEN United States
  • Employees
  • ALVR N/A
  • EYEN N/A
  • Industry
  • ALVR Biotechnology: Biological Products (No Diagnostic Substances)
  • EYEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALVR Health Care
  • EYEN Health Care
  • Exchange
  • ALVR Nasdaq
  • EYEN Nasdaq
  • Market Cap
  • ALVR 87.7M
  • EYEN 38.2M
  • IPO Year
  • ALVR 2020
  • EYEN 2018
  • Fundamental
  • Price
  • ALVR $0.94
  • EYEN $0.55
  • Analyst Decision
  • ALVR Sell
  • EYEN Strong Buy
  • Analyst Count
  • ALVR 5
  • EYEN 2
  • Target Price
  • ALVR $1.00
  • EYEN $12.00
  • AVG Volume (30 Days)
  • ALVR 155.6K
  • EYEN 879.0K
  • Earning Date
  • ALVR 11-04-2024
  • EYEN 11-11-2024
  • Dividend Yield
  • ALVR N/A
  • EYEN N/A
  • EPS Growth
  • ALVR N/A
  • EYEN N/A
  • EPS
  • ALVR N/A
  • EYEN N/A
  • Revenue
  • ALVR N/A
  • EYEN $31,405.00
  • Revenue This Year
  • ALVR N/A
  • EYEN $50,309.30
  • Revenue Next Year
  • ALVR N/A
  • EYEN $421.63
  • P/E Ratio
  • ALVR N/A
  • EYEN N/A
  • Revenue Growth
  • ALVR N/A
  • EYEN N/A
  • 52 Week Low
  • ALVR $0.58
  • EYEN $0.37
  • 52 Week High
  • ALVR $2.49
  • EYEN $2.57
  • Technical
  • Relative Strength Index (RSI)
  • ALVR 69.10
  • EYEN 52.60
  • Support Level
  • ALVR $0.74
  • EYEN $0.52
  • Resistance Level
  • ALVR $0.91
  • EYEN $0.59
  • Average True Range (ATR)
  • ALVR 0.06
  • EYEN 0.05
  • MACD
  • ALVR 0.01
  • EYEN 0.01
  • Stochastic Oscillator
  • ALVR 94.50
  • EYEN 66.45

About ALVR AlloVir Inc.

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

About EYEN Eyenovia Inc.

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Share on Social Networks: